|
CA2645441A1
|
|
Compositions of tolperisone
|
|
WO2009017625A1
|
|
Treatment of depression, phychosis, and anxiety
|
|
WO2008137012A1
|
|
Use of a glial attenuator to prevent amplified pain responses caused by glial priming
|
|
EP2131841A1
|
|
Methods for treating acute pain
|
|
WO2008057496A2
|
|
Method for treating delirium
|
|
WO2007142923A1
|
|
Mif inhibitors for treating neuropathic pain and associated syndromes
|
|
EP2026804A1
|
|
Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
|
|
CA2648533A1
|
|
Method for treating thrombotic disorders using sulfated polysaccharides
|
|
JP2006223315A
|
|
High efficiency helper system for aav vector production
|
|
WO2006130580A2
|
|
Mutant il-10
|
|
EP1901769A2
|
|
Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
|
|
BRPI0518829A2
|
|
Method for the treatment of neuropathic pain and associated syndromes
|
|
JP2006075171A
|
|
Accessory functions for use in recombinant aav virion production
|
|
CN101123919A
|
|
Stepped cannula
|
|
US2006073119A1
|
|
Methods for treating neurodegenerative disorders
|
|
CN101018858A
|
|
Compositions and methods to prevent AAV vector aggregation
|
|
WO2005117912A1
|
|
Methods for treating bleeding disorders using sulfated polysaccharides
|
|
WO2005118614A1
|
|
Methods and compositions for treating neuropathic pain
|
|
WO2004113494A2
|
|
Methods for producing preparations of recombinant aav virions substantially free of empty capsids
|
|
AU2004200160A1
|
|
Adeno-associated viral vector-mediated expression of factor VIII activity
|
